🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Original Article: Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer (ESOPEC trial) nej.md/4apWlo5 Editorial: Multimodal Treatment in Locally Advanced Esophageal Adenocarcinoma — Two Interventions Better Than Three?

Botensilimab with or without balstilimab in refractory MSS CRC with no liver metastases #ASCOGI25 🔎🗺️Phs-2 👉highest with 75 mg BOT / 240 mg BAL > 19% 👉BOT needs BAL 👉Acceptable safety 🧐Finally ICI in CRC? Supports planned phs-3 for combo ESMO - Eur. Oncology

Encorafenib + cetuximab + CTx in BRAF V600E-mutant CRC #ASCOGI25 🔎BREAKWATER 👉ORR 60 vs 40.0%, durable responses in BRAF V600E-mutant mCRC 👉mOS nr vs 14 mo, strong trend! 👉SAE ≥3 37.7% vs 34.6%, no new signals, manageable 🧐Support for a treatment with FDA approval ESMO - Eur. Oncology

1/2 Matching #patients to #clinicaltrials is one of the most important tasks of a molecular tumour board. #OpenAccess in npj Journals #PrecisionOncology evaluates four clinical trial matching tools in this setting. #PrecisionMedicine OncoAlert 🚨 nature.com/articles/s4169…

Adjuvant ICI in patients with resected GC/ GEJ following preoperative CTx with high risk for recurrence Annals of Oncology doi.org/10.1016/j.anno… 🔎EORTC 1707 VESTIGE study 👉Nivo/IPI vs CTx 👉DFS 11.4 vs 20.8 👉12-months DFS 47.vs 64.0%, 👉OS: 27 vs 37 mo 👉Disappointing outcome

Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: doi.org/10.1038/s41591… Nature Medicine 🔎BREAKWATERa phs 3 trial 👉ORR 60 vs 40.0% 👉DoR 13.9 vs11.1 mo 👉OS NE vs 14.6 🧐New SOC for BRAF mutant CRC ESMO - Eur. Oncology

🚨We’ve just published our latest research on chromosomal instability in CRC using PDOs🧫. 👩🏻‍🔬Combining multi-omics & cutting-edge analysis, we uncovered new potential therapeutic targets! 💊 🔗 jeccr.biomedcentral.com/articles/10.11…

Esta semana hemos sabido que el director del VHIO ha sido reconocido como miembro distinguido de la Academia AACR.  🔝 ¡Enhorabuena, Josep Tabernero‼️ 👉 linke.to/TaberneroAACRV… #AACRFellows

SHR-A2102 Nectin-4/Topo-1 ADC with 38% RR & 5.5 mnth PFS in pretreated (~50% prior ADCs) urothelial cancer (n=81). Adverse events focus on top-1 tox (haem). This is the 1st Nectin/topo1 combo & looks more like EV than SG activity-the target maybe more important than the payload.

Single-cell multi-stage spatial evolutional map of esophageal carcinogenesis dlvr.it/TJZYbc

NEW content online! The fibroinflammatory response in cancer bit.ly/4kKexO2

Retrospective analysis of MTB impact on the care of patients with GI tumors at IEO just published in ESMO Open. Among 192 patients discussed at the MTB, 31 (17.7%) were recommended molecularly guided treatment options, experiencing longer rwPFS. esmoopen.com/article/S2059-…

Detailed maps of #mutations in both healthy and cancerous gastric tissue provide insights into how #gastric #cancer develops and may help guide early detection efforts. nature.com/articles/d4158… nature.com/articles/s4158…

The FDA approved perioperative duvalumab with neoadjuvant chemo for muscle invasive bladder cancer today. It’s the only perioperative immune therapy trial with significant OS (0.75). Surgical safety was maintained. NCCN approval recently too #GUtrends25 fda.gov/drugs/resource…

Original Article: Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism (API-CAT trial) nej.md/41YkRZK Editorial: Cancer-Associated Venous Thromboembolism — Beyond 6 Months nej.md/4iB6wcA #ACC25 | American College of Cardiology

Pan-cancer MTAPdel clinical&molecular landscape in ESMO Open. Higher proportion in thoracic, bladder/urinary, pancreatic/biliary tract, CNS, skin tumors. Association with sex, age, tumor aggressiveness, KRASmut (pancreatic cancer). esmoopen.com/article/S2059-…

Systematic review on individualization of systemic therapies for locoregionally advanced NPC in ESMO Open. Extensive review of available clinical data, while waiting for results of studies exploring personalized approaches to (de)escalate treatments. esmoopen.com/article/S2059-…

Today is a special day for LEGACyH2020 project! We are proud Tessa Groen-van Schooten defended her Phd entitled "Defining heterogeneity in the immune infiltrate of gastroesophageal adenocarcinoma". Special thanks to co-supervisors Sarah Derks and Tanja de Gruijl .

🆕Article of the Month podcast🎧: Tom Powles discusses the final results of the phase III JAVELIN Renal 101 trial with Toni Choueiri, MD tinyurl.com/ye7frm92 For the full study report see doi.org/10.1016/j.anno…

📣 Updated ESMO #ClinicalPracticeGuideline on #localised #rectalcancer: tailored intensification/de-intensification, complex radiological factors, #biomarkers & organ-preserving Tx options. #ESMOGuidelines 🔗 ow.ly/q2VV50VWTAU